USABiotech & Genomic Medicine▲
Rocket Pharmaceuticals Completes $180 Million Priority Review Voucher Sale
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million. The voucher was awarded by the FDA in March 2026 following the approval of Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I. Before the transaction, the company reported cash, cash equivalents, and investments of $144.4 million as of March 31, 2026, and the non-dilutive proceeds increased its pro forma cash position to approximately $322.6 million, extending its expected operational runway through the second quarter of 2028. BofA Securities analyst Jason Zemansky recently raised the price target on Rocket Pharmaceuticals to $10 from $9 and maintained a Buy rating, citing the restart of RP-A501 dosing as a positive step in the company's near-term recovery strategy.